Astellas Pharma Inc.
Q1 FY2027 Financial Results Supplement
IFRS-based consolidated results supplement for the first quarter of the fiscal year ending March 2027. Net sales increased year over year; full-year guidance revised to 22,200 billion yen with YoY change indicated. Includes breakdown by key products and regions, currency effects, capital expenditure and depreciation, and adjustments to core earnings. Risks noted include market conditions, exchange rate fluctuations, and delays in new product launches.
Key Figures
- Net sales: 6,409 billion yen (1Q) YoY change: +1,351 billion yen
- Operating income: 1,845 billion yen (1Q) YoY change: +899 billion yen
- Quarterly profit: 1,418 billion yen (1Q) YoY change: +734 billion yen
AI要約
Overview of results
Astellas Pharma's IFRS-based Q1 FY2027 financial results supplement shows a substantial year-over-year increase in net sales, with notable growth in operating income and quarterly net income. Provides breakdowns by region and major product, currency effects, and adjustments to the core basis, with potential implications for revising full-year guidance. The supplement includes updates on new drug development and reference information; risks include market conditions, exchange rate fluctuations, and delays in new product launches.
Outlook and impact for investors
Full-year guidance is indicated at 22,200 billion yen, with emphasis on growth rate YoY and contributions by segment. Currency effects are estimated to positively impact net sales by 60 billion yen and core operating income by 25.5 billion yen. Monitoring of new drug development progress and sales trends for key products is essential, with investors particularly focusing on regional sales composition, approval status of new drugs, and future capital allocation policy (including capital policy-related considerations).
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
